Novak Djokovic ’s Nano Patch: He Calls It His ‘Biggest Secret’—Some Experts Call It Bogus
The patch is called a TaoPatch and is produced by an Italian company that claims the device can boost athletic performance, improve diseases like multiple sclerosis and build stamina. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 13, 2023 Category: Pharmaceuticals Authors: Arianna Johnson, Forbes Staff Tags: Innovation /innovation Science /science Healthcare /healthcare Breaking breaking-news Trending Explainer Trending-Explainer topline Source Type: news
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Investor Update - July 13, 2023 Category: Pharmaceuticals Source Type: news
Stem Cell Medical Tourism Leads to Meningitis in MS Patient
(MedPage Today) -- A woman with multiple sclerosis (MS) who had intrathecal injections of umbilical cord stem cells in Mexico ended up with a severe Mycobacterium abscessus infection that took weeks to identify and treat, according to a case study... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 13, 2023 Category: American Health Source Type: news
Genes Identified in Association With Multiple Sclerosis Severity
FRIDAY, July 7, 2023 -- Authors of a study published online June 28 in Nature have identified genetic markers associated with multiple sclerosis (MS) severity.
Adil Harroud, M.D., from the University of California in San Francisco, and colleagues... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 7, 2023 Category: Pharmaceuticals Source Type: news
Factors contributing to falls in people with multiple sclerosis: the exploration of the moderation and mediation effects - Jawad A, Baattaiah BA, Alharbi MD, Chevidikunnan MF, Khan F.
The prevalence of multiple sclerosis (MS) has significantly increased in recent decades. People with MS have a high risk of falling; these falls may lead to serious injuries, affecting their quality of life PURPOSE: The aim of this study is to assess the f... (Source: SafetyLit)
Source: SafetyLit - July 3, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Preliminary race-ethnicity-based analyses of fall risk among people with multiple sclerosis - Buehler RA, Yang F.
BACKGROUND: Mounting evidence suggests differences in the disease characteristics of multiple sclerosis (MS) across ethnic and racial groups. Although it is widely recognized that falls are a significant concern for people with MS (PwMS), no study has expl... (Source: SafetyLit)
Source: SafetyLit - July 3, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
The effect of balance, walking capacity, and fear of falling on the level of community integration in individuals with Multiple Sclerosis: a cross-sectional study - S öylemez B, Cetisli-Korkmaz N, Tekİn S, Bİr LS, Şenol H.
This study aimed to evaluate to which extent the walking capacity, balance, and fear of falling (FoF) affe... (Source: SafetyLit)
Source: SafetyLit - July 1, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Four-year follow up data for Roche ’s Evrysdi show continued increase in number of children with a severe form of spinal muscular atrophy (SMA) able to sit, stand and walk
Data from ongoing FIREFISH study confirm long-term efficacy and safety profile ofEvrysdi in children with Type 1 SMANinety-one percent of children were alive at month 48More than 95% maintained the ability to swallow- without treatment they would have required feeding support and majority would have died within 2 yearsEvrysdi is now approved in 99 countries with more than 8,500 patients treated globallyBasel, 30 June 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new long-term data for Evrysdi ® (risdiplam) from the open-label extension (n=50) of the pivotal FIREFISH study, reinforcing its sustained efficacy an...
Source: Roche Investor Update - June 30, 2023 Category: Pharmaceuticals Source Type: news
Four-year follow up data for Roche ’s Evrysdi show continued increase in number of children with a severe form of spinal muscular atrophy (SMA) able to sit, stand and walk
Data from ongoing FIREFISH study confirm long-term efficacy and safety profile ofEvrysdi in children with Type 1 SMANinety-one percent of children were alive at month 48More than 95% maintained the ability to swallow- without treatment they would have required feeding support and majority would have died within 2 yearsEvrysdi is now approved in 99 countries with more than 8,500 patients treated globallyBasel, 30 June 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new long-term data for Evrysdi ® (risdiplam) from the open-label extension (n=50) of the pivotal FIREFISH study, reinforcing its sustained efficacy an...
Source: Roche Media News - June 30, 2023 Category: Pharmaceuticals Source Type: news
Rituximab Inferior to Ocrelizumab for MS Relapse Rituximab Inferior to Ocrelizumab for MS Relapse
The relapse rate among patients with relapsing-remitting multiple sclerosis who were treated with rituximab was higher than among those treated with ocrelizumab, results of a noninferiority study suggest.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 29, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Discovery of MS'Severity Gene' Could Lead to Better Treatments
THURSDAY, June 29, 2023 -- For the first time, scientists have identified a genetic variant that may make some people with multiple sclerosis (MS) vulnerable to faster progression.
In a study of more than 22,000 people with MS, researchers found... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 29, 2023 Category: General Medicine Source Type: news
Genetic variant identified that may increase multiple sclerosis severity
Discovery could pave way for new treatments for condition that affects 2.9m people worldwideResearchers have discovered a genetic variant that appears to influence the speed at which multiple sclerosis (MS) progresses, potentially paving the way for new treatments.According to theMS International Federation, about 2.9 million people worldwide have MS, a condition in which the insulating coating of the nerves in the brain and spinal cord is damaged by the immune system. The nerve fibres themselves can also become damaged.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - June 28, 2023 Category: Science Authors: Nicola Davis Science correspondent Tags: Multiple sclerosis Medical research Genetics Science Society Source Type: news
MS Disease Severity Tied to Genetic Variant
(MedPage Today) -- The first genetic variant associated with faster disease progression in multiple sclerosis (MS) has been identified.
In a genome-wide association study (GWAS) of 22,000 people with MS, a significant association between age-related... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - June 28, 2023 Category: Neurology Source Type: news
Genetic variant linked with faster progression of multiple sclerosis
A study of more than 22,000 people with MS has for the first time identified a genetic variant associated with faster progression of the disease. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 28, 2023 Category: Universities & Medical Training Source Type: news
